The Mark Egly Foundation believes that transformative change happens through collaboration. We actively partner with healthcare providers, researchers, institutions, and organizations to rapidly disseminate Mark Egly's groundbreaking discoveries about Alpha-1 Antitrypsin and ensure these insights reach those who need them most.
Our Partnership Mission: Speed the translation of research discoveries into clinical practice, expand access to diagnosis and treatment, and build a global network of AATD experts committed to changing medicine.
Mark's discoveries reveal that Alpha-1 Antitrypsin deficiency and dysfunction could be affecting:
No single organization can tackle this alone. Success requires coordinated effort across specialties, institutions, and nations.
Accelerated Knowledge Dissemination
Enhanced Research Capabilities
Expanded Patient Access
Greater Impact
Individual Clinician Collaborations
We've established partnerships with forward-thinking physicians across multiple specialties who recognize the profound implications of Mark's discoveries.
Specialties Engaged:
What These Partnerships Look Like:
Knowledge Exchange
Patient Care Enhancement
Education and Training
Research Collaboration
University Medical Centers
While we're building our network, we're engaging with academic institutions that have:
Partnership Activities:
Research Collaboration
Clinical Innovation
Education Integration
Specialized AATD Care Facilities
We support and collaborate with Clinical Resource Centers designated by the Alpha-1 Foundation, which provide comprehensive multidisciplinary care for AATD patients.
CRC Network Benefits:
Our Collaboration:
Alpha-1 Foundation
We work alongside the Alpha-1 Foundation, the leading organization dedicated to finding a cure for Alpha-1 and improving lives of those affected.
Complementary Missions:
Areas of Collaboration:
Other Patient Organizations
Industry Collaboration for Innovation
Current Engagement:
Partnership Objectives:
Alternative Production Development
Diagnostic Innovation
Therapeutic Development
Ethical Partnership Framework:
Building Consensus for Change
Current and Target Partnerships:
Partnership Goals:
Training the Next Generation
Medical Schools
Residency and Fellowship Programs
Continuing Medical Education (CME) Providers
Vision: Create a worldwide community of physicians knowledgeable about AATD and committed to early diagnosis, comprehensive treatment, and clinical innovation.
Network Features:
Online Platform
Virtual Events
In-Person Gatherings
Collaborative Research
Current Status:
Join the Network: Healthcare providers interested in joining "Uniting Doctors" can contact us through our website.
Case Study 1: Rheumatology Partnership
A rheumatologist partner read Mark's patent and recognized the connection to his lupus patients. He began testing for AATD and discovered that 30% of his treatment-resistant patients had moderate AAT deficiency. After advocating for AAT augmentation therapy, several patients experienced dramatic improvements in symptoms and reduced medication requirements.
Impact: Changed practice patterns, improved patient outcomes, sparked research study.
Case Study 2: Pulmonology Network Effect
A pulmonologist trained by MEF shared insights with his colleagues at a major hospital system. Within 6 months, AATD testing increased 400% at their facility, leading to 15 new diagnoses and earlier treatment for patients who would have suffered for years undiagnosed.
Impact: Systemic change in institutional practice, multiplicative effect through peer education.
Case Study 3: Medical Student Innovation
A medical student exposed to Mark's research during a lecture developed a research project examining AAT levels in inflammatory bowel disease patients. His findings led to a pilot study at his institution exploring AAT therapy for treatment-resistant IBD.
Impact: Next-generation physician engaged, novel research direction initiated.
Research Institutions
Healthcare Systems
Diagnostic Companies
Technology Partners
Global Health Organizations
Government and Policy
For Healthcare Providers:
For Researchers:
For Institutions:
For Industry:
For Organizations:
Patient-Centered
Evidence-Based
Collaborative Not Competitive
Inclusive and Diverse
Action-Oriented
The scope of Mark Egly's discoveries is too vast for any single organization to address alone. But together—physicians, researchers, institutions, industry, patients, and advocates—we can:
Individual physicians intrigued by Mark's discoveries have already begun changing practice patterns, diagnosing previously missed cases, and improving patient outcomes. As our network grows, this impact multiplies exponentially.
For Partnership Inquiries:
We're eager to connect with anyone committed to advancing Alpha-1 Antitrypsin research, diagnosis, treatment, and awareness.
"Alone we can do so little; together we can do so much."
— Helen Keller
The Mark Egly Foundation: Building partnerships that change medicine and save lives.